ScoreComparison
Why is Avalo Therapeutics, Inc. ?
Unrated Stock - No Analysis Available
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-50.05%
EBIT Growth (5y)
-162.51%
EBIT to Interest (avg)
-31.38
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.33
Tax Ratio
0.16%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.57%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.36
EV to EBIT
1.55
EV to EBITDA
1.56
EV to Capital Employed
-78.19
EV to Sales
-78.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-37.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend5What is working for the Company
NET PROFIT(HY)
Higher at USD -31.76 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
CASH AND EQV(HY)
Highest at USD 238.39 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 26.73 times
-28What is not working for the Company
NET SALES(9M)
At USD 0.19 MM has Grown at -66.37%
OPERATING CASH FLOW(Y)
Lowest at USD -47.42 MM
ROCE(HY)
Lowest at -90.25%
OPERATING PROFIT(Q)
Lowest at USD -19.18 MM
PRE-TAX PROFIT(Q)
Lowest at USD -18.22 MM
NET PROFIT(Q)
Lowest at USD -18.23 MM
Here's what is working for Avalo Therapeutics, Inc.
Cash and Eqv
Highest at USD 238.39 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 26.73 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Avalo Therapeutics, Inc.
Net Sales
At USD 0.19 MM has Grown at -66.37%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -18.22 MM has Fallen at -58.6%
over average net sales of the previous four periods of USD -11.49 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -18.23 MM has Fallen at -58.36%
over average net sales of the previous four periods of USD -11.51 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Operating Cash Flow
Lowest at USD -47.42 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Operating Profit
Lowest at USD -19.18 MM and Fallen
In each period in the last five periodsMOJO Watch
Near term Operating Profit trend is quite negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -18.22 MM and Fallen
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -18.23 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
